Therapeutic Effect Analysis of Cervical Cancer Vaccine
DOI:
https://doi.org/10.62051/b8eajz51Keywords:
Cervical cancer; Therapeutic vaccines; Human papillomavirus.Abstract
Cervical cancer is a very widespread carcinogenic condition that poses a significant threat to women's health. The primary cause of this condition is mostly linked to persistent infection with high-risk strains of human papillomavirus (HPV), which are recognized for their ability to promote the development of cancer. Due to HPV infection, both therapeutic and preventative HPV vaccinations have been developed. Therapeutic vaccines can eradicate viruses and virus-infected cells by stimulating cellular immunity. Notwithstanding the availability of preventive HPV vaccinations, HPV screening, surgery, radiotherapy, and chemotherapy, the therapeutic effect on cervical cancer patients is limited. Therefore, therapeutic vaccines have emerged as a new treatment option. The cancer-causing proteins E6 and E7, which are consistently detected in cervical cancer and precancerous lesions, are crucial in the progression and sustenance of cervical cancer. Consequently, these cancer-causing proteins present an encouraging opportunity for the research and creation of therapeutic cervical cancer vaccines. The multiple therapeutic vaccines against cervical cancer will be briefly discussed in this article, including their mechanisms, development methods, and clinical effects.
Downloads
References
Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 2021, 71 (3): 209 - 249.
Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health, 2020, 8 (2): e191 - e203.
WHO I C O. Human Papillomavirus and Related Diseases Report—WORLD[J]. HPV Inf Cent [Internet], 2014: 1 - 38.
Goradel N H, Mohajel N, Malekshahi Z V, et al. Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches. Journal of cellular physiology, 2019, 234 (6): 8636 - 8646.
Hamley I W. Peptides for vaccine development. ACS Applied Bio Materials, 2022, 5 (3): 905 - 944.
De Sousa L G, Rajapakshe K, Canales J R, et al. ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response. Journal for immunotherapy of cancer, 2022, 10 (2): e004232.
Melief C J M, van der Gracht E, Wiekmeijer A S. Combination immunotherapy with synthetic long peptides and chemotherapy or PD-1 blocker for cancers caused by human papilloma virus type 16//Seminars in Immunopathology. Berlin/Heidelberg: Springer Berlin Heidelberg, 2023, 45 (2): 273 - 277.
Peng S, Tan M, Li Y D, et al. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model. Cancer Immunology, Immunotherapy, 2021, 70: 1049 - 1062.
Choi Y J, Hur S Y, Kim T J, et al. A phase II, prospective, randomized, multicenter, open-label study of GX-188E, an HPV DNA vaccine, in patients with cervical intraepithelial neoplasia 3. Clinical Cancer Research, 2020, 26 (7): 1616 - 1623.
Grunwitz C, Salomon N, Vascotto F, et al. HPV16 RNA-LPX vaccine mediates complete regression of aggressively growing HPV-positive mouse tumors and establishes protective T cell memory. Oncoimmunology, 2019, 8 (9): e1629259.
Cao G, Cui R, Liu C, et al. MTBHsp70-exFPR1-pulsed dendritic cells enhance the immune response against cervical cancer. Journal of Cancer, 2019, 10 (25): 6364.
Downloads
Published
Conference Proceedings Volume
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.







